Cyclacel Pharmaceuticals (NASDAQ:CYCC) Receives New Coverage from Analysts at StockNews.com

Research analysts at StockNews.com initiated coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC – Get Rating) in a research note issued to investors on Wednesday. The firm set a “sell” rating on the biotechnology company’s stock.

Separately, Oppenheimer decreased their target price on Cyclacel Pharmaceuticals from $10.00 to $8.00 and set an “outperform” rating on the stock in a research report on Tuesday, March 7th.

Cyclacel Pharmaceuticals Trading Up 6.6 %

Cyclacel Pharmaceuticals stock opened at $0.68 on Wednesday. Cyclacel Pharmaceuticals has a 12 month low of $0.50 and a 12 month high of $2.41. The stock’s 50 day moving average is $0.60 and its 200-day moving average is $0.78. The company has a market capitalization of $8.50 million, a price-to-earnings ratio of -0.35 and a beta of 1.11.

Cyclacel Pharmaceuticals (NASDAQ:CYCC – Get Rating) last posted its earnings results on Monday, March 6th. The biotechnology company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.12). As a group, equities research analysts predict that Cyclacel Pharmaceuticals will post -1.72 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Cyclacel Pharmaceuticals

Several institutional investors have recently made changes to their positions in the stock. Schonfeld Strategic Advisors LLC boosted its stake in shares of Cyclacel Pharmaceuticals by 25.2% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 770,400 shares of the biotechnology company’s stock valued at $514,000 after buying an additional 155,200 shares during the period. Millennium Management LLC boosted its stake in shares of Cyclacel Pharmaceuticals by 6.5% in the fourth quarter. Millennium Management LLC now owns 208,062 shares of the biotechnology company’s stock valued at $139,000 after buying an additional 12,617 shares during the period. HRT Financial LP bought a new stake in shares of Cyclacel Pharmaceuticals in the fourth quarter valued at approximately $27,000. Two Sigma Investments LP bought a new stake in shares of Cyclacel Pharmaceuticals in the third quarter valued at approximately $98,000. Finally, Renaissance Technologies LLC boosted its stake in shares of Cyclacel Pharmaceuticals by 166.0% in the third quarter. Renaissance Technologies LLC now owns 167,600 shares of the biotechnology company’s stock valued at $245,000 after buying an additional 104,600 shares during the period. 23.77% of the stock is currently owned by institutional investors.

Cyclacel Pharmaceuticals Company Profile

(Get Rating)

Cyclacel Pharmaceuticals, Inc is a clinical stage biopharmaceutical company. It uses cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. The company builds a biopharmaceutical business, which is focused in hematology and oncology based on a pipeline of novel drug candidates.